

FOR IMMEDIATE RELEASE

MEDIA RELEASE

## PHARMANIAGA GIVES BACK TO KELUARGA MALAYSIA WHILST CONTINUING THE FIGHT AGAINST COVID-19

**SHAH ALAM, 19 NOVEMBER 2021** – Pharmaniaga Berhad (Pharmaniaga) remains committed to giving back to the nation and supporting *Keluarga Malaysia* throughout the COVID-19 pandemic by ensuring steady business growth over the long term.

To date, the Group has contributed more than RM17 million, that includes RM6 million towards supporting the frontliners in the Government's healthcare facilities, as well as providing aid to underserved and unprivileged communities. The Group has also allocated zakat of RM11.8 million for the nine-month period ended 30 September 2021.

Contributing towards these efforts are the Group's positive returns and growth momentum in the third quarter of 2021 (Q3FY2021) with Profit After Taxation (PAT) of RM50 million and Profit Before Zakat and Taxation (PBT) of RM98 million on the back of a revenue of RM2.1 billion. Within the nine-month period, the Group has achieved PAT of RM87 million and PBT RM152 million while revenue stood at RM4.1 billion.

Pharmaniaga Group Managing Director Datuk Zulkarnain Md Eusope said that the main contributor to this commendable performance is the 20.4 million supply of Sinovac COVID-19 vaccine to the Ministry of Health (MOH) as well as more than 2 million doses to the private sector.

"The Drug Control Authority has just approved the Sinovac booster shot, and with about 11 million Sinovac recipients in the country, the Group is prepared to supply 10 million doses of the booster shot to MOH and the private market.

"According to a research in China, booster shots given at an interval of six to 12 months after the second dose led to a strong boost in immune response, with higher persistence of antibody of up to 20-fold, indicating a longer duration of protection from COVID-19 and new variants," he said

As for the concession of the logistics and distribution business, Datuk Zulkarnain said that the Group will continue to carry out its duties and responsibilities as MOH's logistic partner until 30 November 2024.

"A series of discussions and negotiations for the renewal of the concession has been carried out and the outcome is very positive. We have an excellent track record of meeting the stringent concession service standards imposed by MOH, further strengthened by our outstanding efforts in managing and delivering the Sinovac

FOR IMMEDIATE RELEASE

**MEDIA RELEASE**

COVID-19 vaccine 4.5 months ahead of schedule, which enabled Malaysia to achieve the 90% vaccination rate for adults much earlier.

"Thus, we are optimistic that MOH will continue to choose Pharmaniaga as its irreplaceable partner to manage the logistics and distribution of pharmaceutical products to its almost 2,000 facilities nationwide," he added.

Pharmaniaga Chairman Dato' Sri Mohammed Shazalli Ramly, echoing the commendable performance said, "Protecting *Keluarga Malaysia* against COVID-19 and supporting the nation's recovery is a key priority for Pharmaniaga.

"We embrace and have embarked on ESG initiatives to end poverty, zero hunger as well as promote good health and well-being, thus have allocated a significant amount from the profit for zakat obligation and to support various sustainable welfare activities to ensure those severely affected by the pandemic are not left behind while the nation is recovering.

"To continue supporting the Malaysian Government to be pandemic-ready in the future, we emphasise R&D efforts which are also the key pillar of growth for Pharmaniaga, enabling us to expand our product pipeline, providing health solutions to the country and *Keluarga Malaysia*. Digitalisation and digital technologies will be the backbone of these efforts," he said.

As a result of this good performance and in line with the Group's commitment to enhancing shareholder value, the Board of Directors declared a third interim dividend of 2.0 sen per share. The dividend will be paid on 29 December 2021 to shareholders on the register as of 7 December 2021.

Pharmaniaga is the leading pharmaceutical Company of the Boustead Holdings Berhad group of companies, and together with Lembaga Tabung Angkatan Tentera, are the major shareholders of the Company.

-END-

FOR IMMEDIATE RELEASE

**MEDIA RELEASE**

**About Pharmaniaga Berhad**

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of the Company. Listed on the Main Board of Bursa Malaysia, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and is empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga Group is positioned to be a regional player in the international pharmaceutical arena.

**Forward-looking statement**

This release may contain certain forward-looking statements with respect to the financial conditions, results of operations and business of the Group and certain plans and objectives of Pharmaniaga Berhad with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

**Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman, Corporate Services Deputy Director of Pharmaniaga Berhad at 03-3342 999 ext 434 or by email [zuhri@pharmaniaga.com](mailto:zuhri@pharmaniaga.com).**